 | Brian Citro Assistant Clinical Professor of Law - Northwestern Pritzker School of Law |
-
01.07.2019-29.07.2019
The Human Rights and Ethical Obligations to Provide Access to New Health Technologies in Countries where Clinical Trials and Public Fiunding Occurred
The objective of this project is three-fold. First, we aim to research and succinctly present the history of the development, clinical trials and availability of bedaquiline and delamanid, and, if time allows, other new TB technologies such as the GeneXpert. To this end, we will identify and highlight relationships between, on the one hand, communities on which trials were conducted and instances where public funding was utilized and, on the other hand, the roll-out and current availability of the new technologies. Second, we aim to examine existing legal, human rights and ethical frameworks to determine if they entail obligations on the part of health technology manufacturers or governments to ensure access to new drugs and diagnostics in countries where clinical trials occurred or where public funding was utilized. Third, based on these findings, we will develop the outline of a normative framework grounded in law, human rights and ethics to clarify the relationship between manufacturers, governments, clinical trial subjects, tax payers and people in need of new drugs and diagnostics.
Brian Citro is an Assistant Clinical Professor of Law at Northwestern Pritzker School of Law in the United States and a Technical Consultant for the UN Development Program and the Stop TB Partnership. Prior to this, he taught at the University of Chicago Law School in the International Human Rights Clinic. He also served as Senior Research Officer to the UN Special Rapporteur on the Right to Health, Anand Grover, and as Project Manager of the Global Health and Human Rights Database at the Lawyers Collective in New Delhi, India.
Précédent